Aim: To provide Registered Nurses description of patient advocacy in the clinical setting.
Design: A qualitative approach with descriptive study design was used to meet the set objective.
Methods: Purposive sampling was used to select the study participants. Through semi-structured interview, data were collected from 25 participants, transcribed and analysed using qualitative content analysis.
Results: The Registered Nurses described patient advocacy as promoting patient safety and quality care which includes the following: protecting patients, being patients' voice, provision of quality care and interpersonal relationship as well as educating patients. The nurses had adequate understanding of patient advocacy and were willing to advocate for patients. There is, however, a need to research into barriers to patient advocacy in the clinical setting. This study made significant contribution to the understanding of patient advocacy and its positive effect on the provision of quality patient care.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6650676 | PMC |
| http://dx.doi.org/10.1002/nop2.307 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Trauma, coping, and adjustment when parenting a child with Dravet syndrome.
Eur J Paediatr Neurol
January 2025
Dravet Syndrome UK, Chesterfield, UK.
Objectives: Dravet syndrome (DS) is a severe developmental and epileptic encephalopathy that requires significant caregiver input across the lifespan. This predominantly falls on parents, who are faced with considerable challenges including physical demands, financial burdens, and sustained pressure on mental wellbeing leading to mental health difficulties. We aimed to develop a grounded theory model for the process of coping and adjustment that occurs when caring for a child who has a diagnosis of DS.
View Article and Find Full Text PDFCenobamate as add-on treatment for SCN8A developmental and epileptic encephalopathy.
Epilepsia
January 2025
Department of Epilepsy Genetics and Personalized Medicine, Danish Epilepsy Center, Dianalund, Denmark.
Objectives: Developmental and epileptic encephalopathies (DEEs) caused by pathogenic variants in SCN8A are associated with difficult-to-treat and early-onset seizures, developmental delay/intellectual disability, impaired quality of life, and increased risk of early mortality. High doses of sodium channel blockers are typically used to treat SCN8A-DEE caused by gain-of-function (GoF) variants. However, seizures are often drug resistant, and only a few patients achieve seizure freedom.
View Article and Find Full Text PDFNavigating the Complexities of Molar Incisor Hypomineralization: Challenges and Strategies in Pediatric Dentistry.
Int J Dent
January 2025
Pediatric Dentistry Department, Faculty of Dentistry, Damascus University, Damascus, Syria.
Molar incisor hypomineralization (MIH) presents a multifaceted challenge in pediatric dentistry, impacting diagnostics, clinical management, resource accessibility, and psychosocial care. The condition's complexity is exacerbated by diagnostic variability, overlapping clinical symptoms, and the need for tailored treatment approaches. This study aims to explore the key challenges associated with the management of MIH in pediatric dentistry, including diagnostic precision, clinical management, resource limitations, interdisciplinary care, long-term follow-up, and psychosocial impact, and to propose strategies for overcoming these obstacles.
View Article and Find Full Text PDFCoronal Malalignment Is Infrequently Present in Patients With Aseptic Tibial Loosening.
Iowa Orthop J
January 2025
Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Background: Coronal lower extremity malalignment and improper implant position have been described as risk factors for aseptic tibial loosening following primary total knee arthroplasty (TKA). However, several prior studies have shown no association between alignment and implant loosening. Meanwhile, there is increasing interest in kinematic alignment.
View Article and Find Full Text PDFEffect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy.
Maturitas
November 2024
Hormone Hamburg, Hamburg, Germany. Electronic address:
Objective: To report patient-reported quality-of-life (QOL) outcomes in the DAYLIGHT study.
Study Design: DAYLIGHT was a phase 3b, randomized, double-blind, 24-week, placebo-controlled study. Participants were women aged ≥40 to ≤65 years with moderate to severe vasomotor symptoms (VMS) considered unsuitable for hormone therapy (HT) (contraindications, caution, stoppers, or averse) randomized 1:1 to placebo or fezolinetant 45 mg once daily.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!